{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+20+mg&page=2", "query": { "intervention": "Dexamethasone 20 mg", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dexamethasone+20+mg&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T23:25:24.410Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02030483", "title": "Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-02", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02030483" }, { "nct_id": "NCT01615029", "title": "Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Part 1 (Dose Escalation): Daratumumab", "type": "DRUG" }, { "name": "Part 2 (Dose Expansion): Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2012-06-26", "completion_date": "2024-10-23", "has_results": true, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01615029" }, { "nct_id": "NCT06126354", "title": "Dexamethasone/Pancreatic Clamp P&F", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance", "Prediabetic State", "Non-Alcoholic Fatty Liver Disease", "Overweight and Obesity" ], "interventions": [ { "name": "Insulin human", "type": "DRUG" }, { "name": "Octreotide Acetate", "type": "DRUG" }, { "name": "Glucagon", "type": "DRUG" }, { "name": "Human Growth Hormone", "type": "DRUG" }, { "name": "Dexamethasone Oral", "type": "DRUG" }, { "name": "[6,6-2H2] D-glucose", "type": "OTHER" }, { "name": "20% D-glucose (aq)", "type": "DRUG" }, { "name": "BOOST Plus", "type": "DIETARY_SUPPLEMENT" }, { "name": "Harvard Apparatus PHD ULTRA CP syringe pump", "type": "DEVICE" }, { "name": "Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer", "type": "DEVICE" }, { "name": "Normal saline", "type": "OTHER" }, { "name": "Human albumin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2024-07-01", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06126354" }, { "nct_id": "NCT03481556", "title": "Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan flufenamide (Melflufen)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncopeptides AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2018-04-12", "completion_date": "2022-02-02", "has_results": true, "last_update_posted_date": "2022-12-19", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03481556" }, { "nct_id": "NCT02404220", "title": "Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Entospletinib", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "CNS Prophylaxis", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2015-05-06", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02404220" }, { "nct_id": "NCT00817479", "title": "Tumor Gene Expression in Women With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "FEMALE", "summary": "18 Years to 59 Years · Female only" }, "enrollment_count": 20, "start_date": "2003-01", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00817479" }, { "nct_id": "NCT04447027", "title": "Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-Cell Lymphoma", "Mature T-cell Malignancies", "Peripheral T-Cell Lymphoma", "Relapsed/ Refractory T-cell Malignancies" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "CC-486 (5-azacitidine)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspiration/Biopsy", "type": "PROCEDURE" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "TTE", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-12-17", "completion_date": "2025-12-17", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04447027" }, { "nct_id": "NCT04910568", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2021-07-26", "completion_date": "2028-12-21", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 6, "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04910568" }, { "nct_id": "NCT03314181", "title": "A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2018-04-02", "completion_date": "2031-05", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 14, "location_summary": "Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03314181" }, { "nct_id": "NCT02292082", "title": "The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Osteoarthritis" ], "interventions": [ { "name": "Bupivacaine", "type": "DRUG" }, { "name": "Morphine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Cefazolin", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Propofol", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "8 MHz. Chiba needle, 22 G / 4 inches", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 111, "start_date": "2014-11", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2019-01-11", "last_synced_at": "2026-09-29T23:25:24.410Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02292082" } ] }